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ABSTRACT 
Purpose:  Cancer diagnosis in adults is often accompanied by negative impacts, which increase 
the risk of depression thereby lowering health related quality of life (HRQoL).  We examined the 
association between depression treatment and HRQoL among US adults with cancer and 
depression. 
Methods:  Patients age 18 and above, with self-reported cancer and depression diagnoses were 
identified from Medical Expenditure Panel Survey database for 2006-2013.  Baseline depression 
treatment was categorized as antidepressants only, psychotherapy with or without antidepressant 
use, and no reported use of antidepressants or psychotherapy.  HRQoL was measured using SF-
12 physical component summary (PCS) and mental component summary (MCS) scores.  
Adjusted ordinary least squares regressions estimated the association between type of depression 
treatment and HRQoL. 
Results:  Out of 450 (weighted per calendar year: 2.1 million) cancer adults included in the 
study, 51% received antidepressants only, while 16% received psychotherapy with or without 
antidepressants.  In bivariate analyses, the mean MCS score was lowest among those who 
received psychotherapy with or without antidepressants compared to those receiving 
antidepressants only and those with no reported use of either modality, p<0.05.  In multivariate 
analyses, there was no significant difference in HRQoL by type of depression treatment. 
Conclusion:  Despite treatment for depression, HRQoL did not improve during the measurement 
timeframe.  Quality of life is a priority health outcome in cancer treatment, yet our findings 
suggest that current clinical approaches to ameliorate depression in cancer patients appear to be 
suboptimal. 
Implications for Cancer Survivors:  Adults with cancer and comorbid depression should 
receive appropriate depression care in order to improve their HRQoL. 
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INTRODUCTION 
Cancer diagnosis in adults is frequently accompanied by negative impacts on mental health, changes in 
body image and function, persistent pain, distress and anxiety, and fear of cancer recurrence and death [1], due to 
which there is an increased risk of depression among adults with cancer [2].  In fact, 25% [1] to 38% [3-5] adults 
with cancer have reported experiencing depression.  Comorbid depression in adults with cancer is negatively 
associated with health-related quality of life (HRQoL) [6, 7], which, in turn, may decrease survival [8].  For 
instance, 16% of breast cancer survivors were reported to be depressed, and depression was inversely associated 
with HRQoL [9].  To improve HRQoL and hence survival in this vulnerable group, adults with cancer and comorbid 
depression should be offered pharmacological and/or psychological treatment for depression [10]. 
Randomized controlled trials (RCTs) studying patients without cancer diagnoses have shown that 
depression treatment improves depression symptoms in a majority of patients [11-13].  Hence, it is highly likely that 
depression treatment, either pharmacological, psychological or both, may improve HRQoL among adults with 
cancer and depression as well.  To our surprise, there is a dearth of data from RCTs regarding the impact of 
depression treatment on HRQoL in patients with cancer.  In fact, the authors of a systematic review on depression 
treatment in cancer patients identified only seven RCTs of pharmacological agents and four RCTs of non-
pharmacological interventions [14].  Of the 11 studies included in the review, only three studies provided data 
describing quality of life measures [15-17].  Fisch et al. detected a significant improvement in quality of life with 
fluoxetine compared to placebo [15], while Razavi et al. identified no significant increase in quality of life scores 
with fluoxetine compared to placebo [16].  A more recent systematic review and meta-analysis [18] examining the 
use of antidepressants for treating depression in cancer patients reported that only three studies [15, 16, 19] included 
quality of life as an outcome.  In addition to Fisch et al. study, Navari et al. also reported a statistically significant 
improvement in quality of life among fluoxetine users compared to those in the placebo group [19].  Yet, another 
systematic review of the effect of cognitive behavioral therapy for depression in adult cancer survivors reported 
improved quality of life with the therapy [20].  An RCT of collaborative care management of depression among 
cancer patients showed improvement in HRQoL, though the study may not be broadly generalizable as it focused on 
low-income, predominantly Hispanic patients [21].  Few studies which evaluated an impact of depression treatment 
on HRQoL have specifically focused on a particular type of cancer.  For instance, studies in women with breast 
cancer reported that treatment of depression, either by pharmacological agents or psychosocial interventions 
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improves quality of life [22, 23] and longevity [22].  Furthermore, a majority of studies evaluated quality of life, 
which is a broad and distinctive construct measuring an overall general well-being, while HRQoL which may 
evaluate physical, social and mental health dimensions, specifically describes health construct using functioning and 
well-being [24]. 
Given that the evidence for the effectiveness of depression treatment on HRQoL in individuals with cancer 
is limited, of questionable quality and not up-to-date, there is a pressing need for further research in this crucial area 
to inform treatment guidelines, clinical decision making and to promote development and/or modifications of 
policies in cancer care.  To our knowledge, there have been no nationally representative studies conducted which 
evaluated the impact of depression treatment on HRQoL among US adults with cancer.  Hence, the primary 
objective of the study was to determine the prevalence of depression treatment among US adults with cancer 
diagnoses and comorbid depression, and examine the association between types of depression treatment and HRQoL 
measures in these patients in a multivariate framework.  We hypothesized that among adults with cancer and 
depression, depression treatment would be associated with superior physical and mental HRQoL compared to those 
who did not report any depression treatment.   
METHODS 
Study design and Data source   
A retrospective longitudinal study design with a baseline period of one year and follow-up period of one 
year was conducted using data from the Medical Expenditure Panel Survey (MEPS).  Sponsored by Agency for 
Healthcare Research and Quality (AHRQ), MEPS provides nationally representative estimates of healthcare use, 
expenditures, source of payment, health insurance coverage, perceived physical and mental health status, HRQoL, 
and health insurance coverage from the US non-institutionalized civilian population [25].  Though MEPS is 
conducted annually, the survey follows individuals for two complete calendar years by interviewing them five times 
to minimize recall bias and to provide data for longitudinal studies [26, 27]. 
For the current study, the first year of observation was used as the baseline period and the second year was 
used as the follow-up period.  In order to obtain adequate sample size, data from seven panels were combined 11 
(2006-2007), 12 (2007-2008), 13 (2008-2009), 14 (2009-2010), 15 (2010-2011), 16 (2011-2012), and 17 (2012-
2013). 
Study cohort 
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The MEPS collects detailed information about medical conditions that are defined as priority conditions by 
AHRQ [28], of which one is cancer.  Adults age 18 years and above with cancer were identified during the baseline 
year using clinical classification codes, 11-44 (except 23 for non-melanoma skin cancer) for cancer from the MEPS 
medical conditions files.  The clinical classification codes are converted to International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) codes, from patient self-reported medical conditions including a 
report of diagnosis and conditions linked with medical events [29].  Adults with cancer who reported depression 
using clinical classification code of 657 and ICD-9-CM codes of 296, 300, and 311 were included in the study [30], 
while those who died during the survey year were excluded from the study as their HRQOL in the follow-up year 
would not be captured.     
Measures 
Dependent variable 
Health Related Quality of Life (HRQoL):  HRQoL was assessed during the follow-up year.  As used in a previous 
study among cancer survivors [31], the summary scores obtained from the second version of the 12-item Short-Form 
Health Survey (SF-12) were used to measure HRQoL.  The SF-12 measures eight constructs: physical functioning, 
role limitations resulting from physical health problems, bodily pain, general health, vitality (energy/fatigue), social 
functioning, role limitation resulting from emotional problems, and mental health.  The MEPS imputes HRQoL 
scores in the physical and mental health domains of HRQoL called the physical component summary (PCS) and the 
mental component summary (MCS) scores, respectively.  The MEPS has rescaled the PCS and MCS scores with 
averages of 50 and standard deviations of 10 with respect to a proprietary US national dataset [32, 33].   
Key independent variable 
Depression treatment:  Depression treatment was measured at baseline and grouped into three categories: (1) no 
report of depression treatment; (2) antidepressant use only; and (3) psychotherapy with or without antidepressants.  
As there were very few individuals with only psychotherapy, those who had psychotherapy with or without 
antidepressants were combined into one group.  Antidepressants use was identified from the prescribed medications 
file using therapeutic class and subclass code of 249 (http://www.multum.com/Lexicon.htm).  MEPS prescribed 
medicine files contain information on therapeutic classes through linkage of Multum Lexicon database 
(http://www.meps.ahrq.gov/mepsweb/data_files/publications/st163/stat163.pdf).  Psychotherapy visits were derived 
from the office-based visits and outpatient visits medical provider visits files.  These files provide visit details 
7 
 
including treatment and procedures obtained during the visit.  Individuals with at least one visit for psychotherapy 
treatment were considered as receiving psychotherapy for depression [34]. 
Other independent variables 
Demographic variables included age (18-39, 40-49, 50-64, 65+), gender (women, men), and race/ethnicity 
(White, African American, Hispanic, other) and marital status (married, widowed/separated/single).  Socioeconomic 
characteristics were measured by education (less than high school, high school graduate, some college), poverty 
status (very poor, near poor, middle income, high income), area of residence (metro, non-metro), and US regions 
(Northeast, South, Midwest, West).  Access to care was measured with health insurance coverage (private, public, 
uninsured), while health status was measured using number of chronic conditions (0, 1, 2+), baseline HRQoL 
scores, type of cancer (breast, lung, prostate/testis, cervical/female genital, colorectal/other gastrointestinal, 
melanoma, and other/non-specified), cancer remission status (yes, no), time since cancer diagnosis (< 2 years, 2-4 
years, 5-9 years, ≥ 10 years).  The co-occurring chronic conditions that were assessed consisted of asthma, arthritis, 
chronic obstructive pulmonary disease, diabetes, gastroesophageal reflux (GERD), heart disease, hypertension, 
osteoporosis, and stroke [31, 35].   
Statistical analyses 
Chi-square statistics were used to determine the significant differences between depression treatment 
categories and other independent variables.  F tests were used to evaluate the unadjusted association between 
depression treatment categories and the HRQoL PCS and MCS scores.  Ordinary least squares (OLS) regressions 
were conducted to evaluate adjusted associations between depression treatment categories and the HRQoL scores.  
Model 1 included depression treatment categories and all the other independent variables excluding baseline 
HRQoL scores, separately for PCS and MCS scores, while Model 2 included depression treatment categories and all 
the other independent variables including baseline HRQoL scores, separately for PCS and MCS scores.  The 
findings that were significant with P values less than 0.05 levels are discussed.  All analyses used the strata, cluster, 
and weights provided in the MEPS data to control for clustering and unequal probability design and were conducted 
in survey procedures using SAS 9.4 (SAS Institute Inc.) to appropriately handle study weights and clustering. 
RESULTS 
The study cohort included 450 adults with cancer diagnoses and comorbid depression who met the 
inclusion criteria.  This represented 18% of the total US adults with cancer (data not shown).  When weighted, this 
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number approximated 2.1 million adults with cancer and comorbid depression for any calendar year within the study 
period.  Table 1 reported the baseline characteristics of the study cohort and the significant differences in the 
characteristics by type of depression treatment.  The majority of the study cohort was age 50 and older (74.8%), 
female (71.7%), white (74.0%), resided in metro areas (83.7%), had some college education (54.2%), had private 
health insurance (66.5%), had at least two comorbidities (59.1%), and had been cancer free for at least 10 years 
(53.3%). 
Overall, 51.1% received antidepressants only, 16.2% received psychotherapy with or without 
antidepressants, and 32.7% reported no depression treatment.  In regard to subgroup differences by types of 
depression treatment, adults age 40 and above with cancer and depression were more likely to receive 
antidepressants compared to their younger counterparts.  While the youngest group in the cohort, those aged 18-39, 
were more likely to not receive any depression treatment.  Married women (56.2%) and those with at least high 
school education (54.0%) were more likely to receive antidepressants compared to their respective counterparts.  
Adults living in a metro area received psychotherapy more frequently than those living in non-metro areas (18.4% 
vs. 4.4%).  Geographically, the Northeast had the highest use of psychotherapy (27.3%) and lowest antidepressant 
use (38.2%), while the south had less use of psychotherapy (8.9%) and more frequent antidepressant use (57.5%).   
Figure 1 depicts rates of depression treatment among adults with cancer and comorbid depression by type 
of cancer.  Our analysis showcased that psychotherapy was used less frequently across all cancer types, with the 
highest rate of use among those with other/non-specified cancers (21.3%) and the least use among those with 
melanoma (1.5%).  Antidepressant use was more frequent than the use of psychotherapy or no treatment across all 
cancer types (range: 46.8-81.1%), except for those with colorectal/other gastrointestinal cancer who were more 
likely to report no depression treatment (53.4%).     
Table 2 highlights the weighted means and standard errors (SE) of HRQoL scores (PCS and MCS) during 
the baseline and follow-up years.  During the baseline year, the mean PCS and MCS scores were 40.11 (SE=0.58) 
and 43.13 (SE=0.60), respectively.  While during the follow-up year, the mean PCS and MCS scores were 40.32 
(SE=0.60) and 43.35 (SE=0.57), respectively.  There were no significant differences in the baseline PCS and MCS 
scores by types of depression treatment.  The result was consistent for the PCS scores in follow-up year with no 
significant differences in scores by types of depression treatment.  However, the mean MCS score in the follow-up 
year was higher among those receiving antidepressants only compared with those who received psychotherapy with 
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or without antidepressants (44.37 vs. 39.23, respectively; p=0.0394).  Appendices 1 and 2 provide the weighted 
means and SE of PCS and MCS scores for each sub-group by types of depression treatment. 
Table 3 reports the regression coefficient estimates (betas) and SE of types of depression treatment 
separately on PCS and MCS scores.  In model 1, after controlling for all the independent variables except baseline 
HRQoL scores, adults with cancer and depression who reported psychotherapy with or without antidepressants had 
higher PCS scores in the follow-up period compared to those without any depression treatment, however, the results 
were not significant (data not shown).  While adults who received antidepressants had nonsignificant lower PCS 
scores compared to those without any depression treatment (data not shown).  In model 2, after controlling for 
baseline HRQoL in addition to other independent variables, the findings remained consistent with model 1.  With 
regard to the MCS scores, adults with cancer and depression who reported either antidepressant use or 
psychotherapy had nonsignificant lower scores compared to those who received no depression treatment in model 1.  
In model 2, after controlling for baseline HRQoL as well, the findings remained consistent with model 1 for 
psychotherapy, while those with antidepressant use had higher MCS scores compared to those who reported no 
depression treatment.  Regardless of these differences, none of these estimates were statistically significant. 
DISCUSSION 
 Considering the high prevalence of depression and its negative impact on HRQoL and mortality among 
adults with cancer, it is highly concerning that only few trials have assessed the efficacy of depression treatment on 
HRQoL among this vulnerable group.  To the authors’ knowledge, this study is first of its kind to evaluate the 
association between depression treatment and HRQoL among adults with cancer and depression in the real-world 
using a nationally representative data.  One third of the study cohort reported no use of depression treatment 
including antidepressants and/or psychotherapy, a finding significantly lower than that reported in the literature [36, 
37].  Walker et al. reported that 73% of the cancer patients with depression did not receive any potentially effective 
depression treatment [36].  One could argue that limited evidence of the efficacy of depression treatment from the 
RCTs could be one of the causes of under treatment of depression among adults with cancer.  Moreover, use of other 
forms of strategies and interventions such as spirituality and spiritual coping, and participation in psychosocial 
support activities not captured by MEPS may be utilized by this group.  Consistent with the literature [38, 39], there 
is an increased use of antidepressants (with or without psychotherapy) in the study cohort (total = 63%).   
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The established average baseline PCS and MCS norms for the nationally representative sample of adults 
with depression are 45.6 and 37.4, respectively [40].  While, for our study sample with cancer and comorbid 
depression, the PCS score is lower and the MCS score is higher than reported for adults with depression only.  These 
findings indicate that cancer may lower physical functioning thereby affecting PCS component of the HRQoL.  
However, the average baseline PCS and MCS scores and hence HRQoL for adults with cancer and depression were 
lower compared to the norm for the adults with cancer (mean PCS: 43.0; mean MCS: 50.1) [31], indicating 
detrimental effect of depression on HRQoL and hence suggesting effective management of depression.  In an 
unadjusted analysis, there were no significant differences in the PCS scores by type of depression treatment after 
one year follow up.  While those who reported antidepressant use only had significantly higher MCS scores, 
followed by those with no depression treatment and psychotherapy (with or without antidepressants) use.  In the 
fully adjusted model, the significance disappeared demonstrating that depression treatment was not associated with 
an improvement in HRQoL scores during the study timeframe in this vulnerable group.  These findings were 
contrasting to those reported in the previous studies which evaluated impact of depression treatment on quality of 
life among cancer patients [15, 19-21]. 
Although HRQoL is a priority health outcome in cancer treatment, the study findings exhibit that current 
depression management to ameliorate HRQoL among adults with cancer may be inadequate.  A system of care 
which addresses all the shortcomings of current depression care is critically needed.  For instance, highly efficacious 
complex interventions such as ‘Depression Care for People with Cancer’ [41] comprising of education about 
depression and its treatment, problem-solving treatment to develop coping strategies, and communication about 
management of depression with each patient’s oncologist and primary care physician supplemental to usual source 
of care, could be developed and implemented to improve depression outcomes and HRQoL among adults with 
cancer and comorbid depression.  Another efficacious intervention, collaborative telecare management 
supplemented with automated symptom monitoring, may also be implemented to improve HRQoL among this 
vulnerable group [42].  As there is modest evidence supporting pharmacological and psychotherapeutic 
interventions for depression among adults with cancer [14, 43, 44], a more definitive evidence from larger high 
powered clinical trials is needed [45]. 
This study utilized a nationally representative survey data to evaluate the association between depression 
treatment and HRQoL among adults with cancer and depression and provided the national estimates.  A 
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comprehensive list of covariates was included to control for confounding bias when assessing the association.  ‘No 
depression’ treatment was used as a comparison group to examine the effectiveness of depression treatment in real-
world settings.  Though this study presents nationally representative estimates, there are limitations worth noting.  
Data is all self-reported and hence prone to recall bias.  The study included adults with diagnosed depression and 
hence those with undiagnosed depression were not included.  Also, duration and severity of depression which may 
impact HRQoL were not assessed and hence was not accounted for in the regression model.  Moreover, though the 
study utilized longitudinal retrospective observational cohort design, causality could not be established.  Though a 
comprehensive list of covariates was included to control for potential confounding bias, clinical information of 
cancer was not available and hence not controlled for in the study.  However, time since cancer diagnosis and 
remission status were captured and included as covariates in the study.  Since the PCS and MCS scores derived from 
the SF-12 are deemed by few researchers to provide meagre intuitive information, we calculated age-specific mean 
PCS and MCS scores [46] and evaluated the association between depression treatment and HRQoL.  There were no 
significant differences in the strength and direction of the estimates (data not shown).  Lack of information on 
initiation and duration of depression treatment may affect the estimates, however, we controlled for depression 
treatment use in the follow-up period which did not impact the direction and strength of the estimates (data not 
shown).  With regard to psychotherapy, two groups, psychotherapy use with antidepressants and psychotherapy 
only, were combined due to a smaller sample size in psychotherapy only group (3.8%) and hence the difference in 
the association between these two groups was not assessed.  Future research should investigate the separate impacts 
of psychotherapy with antidepressants and psychotherapy only on HRQoL among adults with cancer and depression 
to identify the effective modality.   
Despite the above limitations, this study evaluated the association between depression treatment and 
HRQoL among adults with cancer and comorbid depression using nationally representative survey data.  The study 
findings suggested that use of antidepressants or psychotherapy did not favorably impact HRQoL among this 
vulnerable group.  Though quality of life is a priority health outcome in cancer treatment, the study implies current 
clinical approaches to ameliorate depression in cancer patients may be inadequate. 
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Table 1 
Characteristics of Adults with Cancer and Comorbid Depression 
By Type of Depression Treatment 
Medical Expenditure Panel Survey, Panels 2006-2013 
       
    
Total (UnWt 
N (Wt%)) 
No Depression 
Treatment 
(UnWt N 
(Wt%)) 
Antidepressa
nts Only 
(UnWt N 
(Wt%)) 
Psychotherapy 
with or without 
Antidepressants 
(UnWt N 
(Wt%)) p-value 
       All     149 (32.7%) 226 (51.1%) 75 (16.2%)  -  
       Age 
     
0.0057 
 
18-39 48 (8.9%) 17 (36.9%) 14 (28.9%) 17 (34.2%) 
 
 
40-49 71 (16.3%) 21 (30.8%) 36 (49.7%) 14 (19.5%) 
 
 
50-64 166 (36.2%) 46 (29.1%) 88 (51.5%) 32 (19.4%) 
 
 
65,+ 165 (38.6%) 65 (36.0%) 88 (56.5%) 12 (7.5%) 
 Gender 
     
0.3313 
 
Female 324 (71.7%) 97 (31.2%) 169 (51.5%) 58 (17.3%) 
 
 
Male 126 (28.3%) 52 (36.7%) 57 (50.1%) 17 (13.2%) 
 Race/Ethnicity 
    
0.1063 
 
White 272 (74.0%) 91 (33.2%) 145 (52.0%) 36 (14.8%) 
 
 
Black 38 (3.5%) 17 (48.2%) 14 (34.0%) 7 (17.8%) 
 
 
Hispanic 46 (5.3%) 15 (32.1%) 19 (40.2%) 12 (27.7%) 
 
 
Other 94 (17.2%) 26 (27.8%) 48 (54.0%) 20(18.2%) 
 Marital Status 
    
0.0340 
 
Married 217 (53.5%) 74 (31.7%) 118 (56.2%) 25 (12.1%) 
 
 
Single/Widowe
d/Divorced 233 (46.5%) 75 (33.9%) 108 (45.3%) 50 (20.8%) 
 Education 
    
0.0154 
 
LT HS 100 (15.7%) 37 (40.6%) 39 (40.9%) 24 (18.5%) 
 
 
HS 140 (30.1%) 52 (36.7%) 74 (54.0%) 14 (9.3%) 
 
 
Some College 210 (54.2%) 59 (28.1%) 113 (52.6%) 38 (19.3%) 
 Poverty Status 
    
0.0007 
 
Very Poor  102 (14.8%) 28 (24.1%) 43 (44.7%) 31 (31.2%) 
 
 
Near Poor  101 (20.9%) 40 (41.2%) 48 (44.8%) 13 (14.0%) 
 
 
Middle Income 115 (29.0%) 45 (40.6%) 58 (49.1%) 12 (10.3%) 
 
 
High Income 132 (35.3%) 36 (24.9%) 77 (59.3%) 19 (15.8%) 
 Health Insurance 
    
0.0693 
 
Private 253 (66.5%) 86 (33.7%) 135 (52.1%) 32 (14.2%) 
 
 
Public  171 (29.3%) 50 (27.9%) 82 (50.6%) 39 (21.5%) 
 
 
Uninsured  26 (4.2%) 12 (50.4%) 9 (38.7%) 5 (10.9%) 
 Chronic conditions 
    
0.1588 
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Table 1 
Characteristics of Adults with Cancer and Comorbid Depression 
By Type of Depression Treatment 
Medical Expenditure Panel Survey, Panels 2006-2013 
       
    
Total (UnWt 
N (Wt%)) 
No Depression 
Treatment 
(UnWt N 
(Wt%)) 
Antidepressa
nts Only 
(UnWt N 
(Wt%)) 
Psychotherapy 
with or without 
Antidepressants 
(UnWt N 
(Wt%)) p-value 
       All     149 (32.7%) 226 (51.1%) 75 (16.2%)  -  
 
0  82 (18.5%) 31 (32.5%) 38 (53.4%) 13 (14.1%) 
 
 
1  94 (22.5%) 35 (41.1%) 45 (47.6%) 14 (11.3%) 
 
 
2,+  274 (59.1%) 83 (29.6%) 143 (51.8%) 48 (18.6%) 
 Location 
     
0.0031 
 
Metro 368 (83.7%) 119 (32.5%) 179 (49.1%) 70 (18.4%) 
 
 
Non-metro 82 (16.3%) 30 (33.9%) 46 (61.8%) 6 (4.4%) 
 US Region 
    
0.0156 
 
Northeast 71 (16.6%) 25 (34.5%0 28 (38.2%0 18 (27.3%) 
 
 
Midwest  95 (19.4%) 25 (29.7%) 52 (54.6%) 18 (15.7%) 
 
 
South 174 (39.5%) 63 (33.6%) 94 (57.5%) 17 (8.9%) 
 
 
West 110 (24.5%) 36 (32.6%) 52 (46.7%) 22 (20.7%) 
 Time Since Cancer Diagnosis 
   
0.0050 
 
LT 2 years 35 (6.6%) 14 (49.4%) 16 (44.2%) 5 (6.4%) 
 
 
2-4 years  92 (22.1%) 23 (24.5%) 51 (57.3%) 18 (18.2%) 
 
 
5-9 years 77 (18.0%) 18 (19.5%) 45 (62.4%) 14 (18.1%) 
 
 
GE 10 years 246 (53.3%) 94 (38.6%) 112 (45.6%) 40 (15.8%) 
 Remission Status 
    
0.8862 
 
Yes 413 (92.8%) 139 (33.1%) 205 (50.7%) 69 (16.2%) 
 
 
No 37 (7.2%) 10 (30.0%) 20 (54.6%) 7 (15.5%) 
               
       UnWt: Unweighted; N: Sample; Wt: Weighted; LT: less than; GE: greater than; HS: high school 
Unweighted N will not necessarily be equal to weighted % due to sample weights being applied to the unweighted 
N.  
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Table 2 
Weighted Means and Standard Errors of Health-Related Quality of Life Scores During Baseline and Follow-
up Year 
Among Adults with Cancer and Comorbid Depression 
By Type of Depression Treatment 
Medical Expenditure Panel Survey, Panels 2006-2013 
       
Category   All 
No Depression 
Treatment 
Antidepressants 
Only 
Psychotherapy 
with or without 
Antidepressants  
    Mean (SE) Mean (SE) Mean (SE) Mean (SE)  
      
 
PCS Scores 
    
 
 
Baseline 40.11 (0.58) 39.50 (0.50) 40.60 (0.63) 39.79 (0.90)  
 
Follow-up 40.32 (0.60) 40.72 (0.46) 39.87 (0.72) 40.97 (0.59)  
MCS Scores 
    
 
 
Baseline 43.13 (0.60) 43.78 (0.30) 44.14 (0.77) 38.63 (0.61)  
 
Follow-up* 43.35 (0.57) 43.78 (0.29) 44.37 (0.76) 39.23 (0.53)  
              
       *Significant differences in MCS scores by type of depression treatment (p=0.034) 
PCS: Physical Component Survey; MCS: Mental Component Survey; SE: Standard Error 
 
 
Table 3 
Parameter Estimates and Standard Errors of Types of Depression Treatment 
From Ordinary Least Squares Regressions on 
Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores 
During Follow-up Among Adults with Cancer and Comorbid Depression 
Medical Expenditure Panel Survey, Panels 2006-2013 
          PCS MCS 
    Beta (SE) 
 
Beta (SE) 
 Model 2: Adjusted for all the independent variables in addition to baseline HRQoL scores 
 
 
No Depression Treatment Reference group Reference group 
 
Antidepressants Only*  -1.01 (0.52)  0.40 (0.81)  
 
Psychotherapy with or without 
Antidepressants* 0.10 (0.98)   -0.86 (1.10)  
            
      *Mean PCS and MCS scores are not significantly different from the reference group (No depression treatment). 
HRQoL: Health-Related Quality of Life; PCS: Physical Component Survey; MCS: Mental Component Survey; SE: 
Standard Error 
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R2 for Model 2: PCS = 0.735, MCS = 0.490 
 
 
 
 
Figure 1: Rates of Depression Treatment by Type of Cancer Among Adults with Cancer 
and Comorbid Depression 
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Appendix 1 
Weighted Means and Standard Errors of PCS Scores of Adults with Cancer and Comorbid Depression 
By Type of Depression Treatment 
Medical Expenditure Panel Survey, Panels 2006-2013 
       
    
 
No 
Depression 
Treatment 
Antidepressants 
Only 
Psychotherapy 
with or without 
Antidepressants p-value 
       Age 
 
    <.0001 
 
18-39  49.95 (1.78) 55.16 (2.26) 43.66 (4.08) 
 
 
40-49  40.59 (2.74) 44.31 (1.96) 38.35 (2.48) 
 
 
50-64  41.34 (1.39) 39.63 (1.24) 40.13 (2.45) 
 
 
65 +  38.11 (0.87) 36.61 (1.34) 43.05 (3.22) 
 
Gender 
 
    0. 4873 
 
Female  41.82 (0.95) 38.99 (1.03) 39.96 (2.09) 
 
 
Male  38.32 (1.49) 42.15 (1.78) 44.31 (1.81) 
 
Race/Ethnicity 
 
   0.0241 
 
White  41.10 (0.97) 39.34 (1.06) 41.94 (2.21) 
 
 
Black  35.24 (3.52) 35.10 (1.84) 31.90 (2.65) 
 
 
Hispanic  38.98 (1.77) 39.98 (2.75) 37.79 (1.66) 
 
 
Other  41.25 (1.66) 42.62 (2.10) 40.87 (1.89) 
 
Marital Status 
 
   0.8224 
 
Married  38.78 (1.10) 40.76 (1.09) 43.40 (2.80) 
 
 
Single/Widowed/Divorced  42.79 (1.18) 38.60 (1.56) 39.35 (1.90) 
 
Education 
 
   <.0001 
 
LT HS  33.30 (1.72) 30.78 (1.74) 36.45 (2.05) 
 
 
HS  38.20 (1.57) 34.19 (1.25) 41.74 (3.81) 
 
 
Some College  45.86 (0.90) 45.15 (1.16) 42.01 (2.13) 
 
Poverty Status 
 
   <.0001 
 
Very Poor  32.94 (2.46) 33.32 (2.11) 37.18 (1.57) 
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Appendix 1 
Weighted Means and Standard Errors of PCS Scores of Adults with Cancer and Comorbid Depression 
By Type of Depression Treatment 
Medical Expenditure Panel Survey, Panels 2006-2013 
       
    
 
No 
Depression 
Treatment 
Antidepressants 
Only 
Psychotherapy 
with or without 
Antidepressants p-value 
       
 
Near Poor  40.16 (0.92) 36.63 (1.87) 36.55 (2.96) 
 
Middle Income  40.59 (1.67) 39.04 (1.87) 42.70 (5.36) 
 
 
High Income  44.58 (1.33) 43.94 (1.42) 45.47 (2.84) 
 
Health Insurance 
 
   <0.0001 
 
Private  42.18 (0.98) 42.44 (1.13) 45.38 (2.32) 
 
 
Public  37.52 (1.45) 33.15 (1.34) 34.45 (1.75) 
 
 
Uninsured  37.46 (3.59) 46.33 (2.47) 39.91 (5.56) 
 
Chronic conditions 
 
   <0.0001 
 
0  46.76 (1.33) 52.07 (1.54) 48.20 (2.46) 
 
 
1  43.87 (1.08) 45.43 (1.78) 38.19 (2.50) 
 
 
2,+  36.98 (1.20) 33.99 (0.99) 39.79 (1.99) 
 
Location 
 
    0.0776 
 
Metro  41.75 (0.91) 40.11 (0.94) 41.29 (1.66) 
 
 
Non-metro  35.61 (2.11) 38.88 (2.25) 34.00 (3.19) 
 
US Region 
 
   0.0066 
 
Northeast  43.85 (2.43) 40.73 (1.73) 47.13 (2.13) 
 
 
Midwest  38.57 (2.10) 41.97 (1.79) 40.68 (2.81) 
 
 
South  40.69 (1.24) 37.23 (1.26) 36.12 (3.00) 
 
 
West  40.05 (1.55) 42.67 (2.12) 38.99 (3.32) 
 
Time Since Cancer Diagnosis 
 
  0.3234 
 
LT 2 years  47.81 (2.44) 35.54 (3.37) 44.74 (6.95) 
 
 
2-4 years  37.67 (2.02) 43.65 (2.10) 40.59 (2.63) 
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Appendix 1 
Weighted Means and Standard Errors of PCS Scores of Adults with Cancer and Comorbid Depression 
By Type of Depression Treatment 
Medical Expenditure Panel Survey, Panels 2006-2013 
       
    
 
No 
Depression 
Treatment 
Antidepressants 
Only 
Psychotherapy 
with or without 
Antidepressants p-value 
       
 
5-9 years  36.27 (1.96) 38.78 (1.85) 38.52 (3.78) 
 
GE 10 years  41.15 (1.00) 38.91 (1.30) 41.91 (2.13) 
 
Remission Status 
 
   0.0007 
 
Yes  41.48 (0.88) 10.09 (0.84) 42.04 (1.46) 
 
 
No  29.80 (2.28) 38.74 (2.69) 26.37 (4.37) 
 
              
       Wt: Weighted; LT: less than; GE: greater than; HS: high school 
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Appendix 2 
Weighted Means and Standard Errors of MCS Scores of Adults with Cancer and Comorbid Depression 
By Type of Depression Treatment 
Medical Expenditure Panel Survey, Panels 2006-2013 
       
    
 
No Depression 
Treatment 
Antidepressants 
Only 
Psychotherapy 
with or 
without 
Antidepressant
s p-value 
       Age 
 
    0.0016 
 
18-39  37.59 (2.76) 42.11 (3.44) 37.07 (1.99)  
 
40-49  48.27 (1.00) 41.87 (1.68) 33.07 (4.34)  
 
50-64  40.37 (1.48) 44.64 (1.17) 38.37 (2.05)  
 
65+  46.19 (0.94) 45.33 (1.50) 50.31 (2.70)  
Gender 
 
    0.4875 
 
Female  45.39 (0.78) 43.81 (0.90) 39.65 (2.20)  
 
Male  40.31 (1.29) 45.82 (1.64) 37.83 (1.75)  
Race/Ethnicity 
 
   0.0802 
 
White  43.55 (0.85) 44.93 (1.00) 38.66 (2.42)  
 
Black  48.00 (2.84) 40.09 (2.09) 31.39 (2.59)  
 
Hispanic  40.91 (1.87) 42.89 (2.20) 32.71 (2.06)  
 
Other  44.48 (1.54) 42.91 (1.77) 45.80 (1.86)  
Marital Status 
 
   0.0512 
 
Married  43.56 (0.74) 45.98 (1.25) 39.64 (2.84)  
 
Single/Widowed/Divorced  44.02 (1.22) 42.07 (1.07) 38.96 (2.14)  
Education 
 
   0.0023 
 
LT HS  39.33 (2.32) 40.32 (2.42) 34.81 (2.32)  
 
HS  43.96 (1.09) 42.29 (1.42) 42.72 (4.57)  
 
Some College  45.38 (1.01) 46.46 (0.94) 39.52 (2.18)  
Poverty Status 
 
   <0.0001 
 
Very Poor  34.30 (1.62) 38.21 (1.47) 34.83 (1.55) 
 
 
Near Poor  40.11 (1.17) 43.04 (1.66) 34.95 (4.66) 
 
 
Middle Income  45.44 (1.34) 42.02 (1.79) 42.04 (3.46) 
 
 
High Income  48.99 (1.22) 48.50 (1.09) 43.61 (2.94) 
 
Health Insurance 
 
   <0.0001 
 
Private  44.91 (0.70) 44.97 (1.10) 41.8 (2.79) 
 
 
Public  43.67 (1.62) 43.55 (1.38) 34.69 (1.55) 
 
 
Uninsured  32.18 (1.39) 38.87 (1.91) 49.04 (1.25) 
 Chronic conditions 
 
   0.1754 
23 
 
Appendix 2 
Weighted Means and Standard Errors of MCS Scores of Adults with Cancer and Comorbid Depression 
By Type of Depression Treatment 
Medical Expenditure Panel Survey, Panels 2006-2013 
       
    
 
No Depression 
Treatment 
Antidepressants 
Only 
Psychotherapy 
with or 
without 
Antidepressant
s p-value 
       
 
0  43.49 (1.81) 46.94 (1.52) 41.58 (4.54)  
 
1  44.78 (1.34) 46.14 (1.11) 32.39 (3.68)  
 
2,+  43.35 (1.00) 42.92 (1.20) 40.26 (1.93)  
Location 
 
    0.9260 
 
Metro  44.09 (0.64) 44.13 (0.84) 39.80 (1.76)  
 
Non-metro  42.26 (2.35) 45.31 (2.26) 26.91 (4.79)  
US Region 
 
   0.3352 
 
Northeast  44.26 (1.93) 42.88 (2.60) 42.09 (2.21)  
 
Midwest  44.69 (0.92) 46.08 (1.68) 42.78 (3.00)  
 
South  42.61 (1.11) 44.04 (1.25) 34.53 (4.40)  
 
West  44.71 (1.41) 44.25 (1.64) 37.80 (3.10)  
Time Since Cancer Diagnosis 
 
  0.0598 
 
LT 2 years  48.17 (1.80) 46.25 (2.05) 38.73 (3.31) 
 
 
2-4 years  38.52 (1.82) 44.46 (1.62) 40.00 (4.85) 
 
 
5-9 years  50.60 (1.91) 44.25 (1.96) 34.16 (2.87) 
 
 
GE 10 years  43.31 (0.75) 44.15 (1.27) 40.86 (1.92) 
 
Remission Status 
 
   0.1995 
 
Yes  43.60 (0.70) 44.7 (0.89) 40.08 (1.76) 
 
 
No  46.34 (2.82) 41.26 (2.42) 27.76 (2.55) 
               
Wt: Weighted; LT: less than; GE: greater than; HS: high school 
 
